Navigation Links
CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis
Date:6/17/2013

SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from a pooled analysis of data from completed Phase 1 and 2 studies of pacritinib, an oral JAK2/FLT3 inhibitor, demonstrating the safety and tolerability profile of pacritinib in patients with myelofibrosis. An integrated safety analysis of four completed Phase 1 and 2 studies totaled 191 patients who were treated with pacritinib for myeloid, primarily myelofibrosis, or lymphoid malignancies to quantify clinical toxicities, with a focus on hematologic effects. Other JAK2 inhibitors have generally been associated with increases in anemia and thrombocytopenia but this was not observed with pacritinib. This integrated safety data analysis showed that, regardless of initial platelet counts, pacritinib causes minimal further marrow suppression. Even patients with initial platelet counts <50,000/µL, a high-risk population, tolerated therapy, maintained stable blood and platelet counts and did not require dose reductions for thrombocytopenia. Grade 1 or 2 gastrointestinal events, particularly diarrhea, were the most common adverse events and may be controlled by early administration of standard anti-diarrheal agents. The analysis was presented during a poster session at the 18th Congress of the European Hematology Association (EHA) held June 13-16, 2013 in Stockholm, Sweden. 

Pacritinib is currently being evaluated in a randomized Phase 3 clinical trial, known as PERSIST-1, in patients with myelofibrosis. Because of pacritinib's relative lack of bone marrow suppression, there are no study entry restrictions due to thrombocytopenia or anemia and patients with platelet and red blood cell transfusion dependence are allowed to enroll in the ongoing PERSIST-1 trial. More details on this study can be found at www.clinicaltrials.gov. Pa
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Zimmer Announces Quarterly Dividend for Second Quarter of 2013
2. Uroplasty Announces Delay in Filing Form 10-K
3. Cempra Announces Proposed Public Offering of Common Stock
4. Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
5. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
6. Royalty Pharma Announces Offer May Lapse (Be Withdrawn)
7. Anthera Pharmaceuticals Announces Personnel Changes
8. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
9. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
10. HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
11. Misonix, Inc. Announces the Grant of Patent by the United States Patent and Trademark Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... Mich. , May 4 Stryker‘s Communications ... have signed an agreement to integrate both companies’ technologies ... this collaboration, operating rooms containing the da ... System will provide surgeons and OR staff more flexibility ...
... Two Roche employees were recognized for their significant ... TWIN Awards Dinner held April 29 , 2010.  Honored were ... M. Fieldstad , Pharm.D., global head, Safety Compliance, Pharmaceutical Development Safety and ... "These women ...
Cached Medicine Technology:Stryker Enters Strategic Marketing Agreement With Intuitive Surgical 2Stryker Enters Strategic Marketing Agreement With Intuitive Surgical 3Roche Women Honored as 2010 TWIN Awardees 2Roche Women Honored as 2010 TWIN Awardees 3Roche Women Honored as 2010 TWIN Awardees 4Roche Women Honored as 2010 TWIN Awardees 5
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... P&C Industry Transactions Gateway Multiplies Direct Connectivity with ... States Move to Adopt eBill Regulations CONCORD, ... Property and Casualty industry supplier of EDI Gateway ... providers and payers nationwide. Network expansion enables Jopari ...
... O,Rourke, MD, Associate Professor of Neurosurgery at the University ... to accurately predict the specific genetic mutation that caused ... magnetic resonance imaging (MRI). The researchers presented their findings ... 100th Annual Meeting 2009. , "The field of cancer ...
... in poor areas more of an issue than youngsters, tastes, ... nutrition may be more an issue of supply than demand ... A new study found that children in these rural areas ... research shows these products are not readily available and could ...
... 2009) New research published in the April issue ... Surgeons suggests that, among surgeons inexperienced in laparoscopic ... less time to learn and results in improved outcomes ... with freehand laparoscopy. , Laparoscopic suturing a ...
... April 15, 2009, ten members of the American Society of ... attended more than a dozen meetings scheduled with key Congressional ... of transplant related issues on Capitol Hill. The Fly ... , AST discussed healthcare ...
... In study on rats, protection eludes those exposed as ... and the estrogen hormone they produce might help protect ... caused by the active ingredient in marijuana, Louisiana State ... , The protection did not seem to apply, ...
Cached Medicine News:Health News:Jopari Further Expands Nationwide Medical Billing Network Connectivity for Workers' Comp and Auto Providers and Payers 2Health News:Jopari Further Expands Nationwide Medical Billing Network Connectivity for Workers' Comp and Auto Providers and Payers 3Health News:First noninvasive technique to accurately predict mutations in human brain tumors 2Health News:Kids and Veggies: Offer Them and They Will Eat 2Health News:Robot improves suture proficiency more rapidly for surgeons inexperienced in laparoscopic techniques 2Health News:Robot improves suture proficiency more rapidly for surgeons inexperienced in laparoscopic techniques 3Health News:AST Leaders Fly to Capitol Hill to Garner and Secure Support for Transplantation Initiatives 2Health News:Estrogen May Combat Marijuana's Effect on Cognition 2
... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 15.0 mm....
For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
Medicine Products: